In the UK, surveys published in 2026 estimated that approximately 1.6 million adults (about 2.9%) had used GLP-1 or GLP-1/GIP medications, such as semaglutide and tirzepatide (Mounjaro), to support weight loss in the past year
Table of Contents Have you experienced dizziness or vertigo and persistent fatigue or weakness, and do you feel these symptoms might be connected
Semaglutide acts on GLP1 receptors
Individuals with active gallbladder disease, severe gastroparesis, or unstable cardiovascular conditions require individualised risk assessment
Funding This work was partially supported by National Institutes of Health NORC Center Grants P30DK072476, Pennington/Louisiana, P30DK040561, Harvard, and R01DK109008, Shape UP